stockportfolio.pro
Stocks / ALT vs DNA
ALT vs DNA
Altimmune, Inc. and Ginkgo Bioworks Holdings, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Altimmune, Inc. (ALT) | Ginkgo Bioworks Holdings, Inc. (DNA) | |
|---|---|---|
| Market cap | $0.5B | $0.5B |
| Revenue (latest FY) | $41,000 | $170.16M |
| Net income (latest FY) | $-88.09M | $-312.76M |
| Revenue growth (5y CAGR) | -65.3% | 17.3% |
| Net margin | -214861.0% | -183.8% |
| Return on equity | -39.2% | -61.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALT — free Open DNA — freeFrequently asked questions
Which is bigger, ALT or DNA?
Altimmune, Inc. is larger by market capitalization — $0.5B versus $0.5B.
Which grows faster, ALT or DNA?
Over the last five fiscal years, Ginkgo Bioworks Holdings, Inc. grew revenue faster — 17.3%/yr versus -65.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.